A library construction method for detecting FH and MED12 gene mutations in uterine leiomyoma based on high-throughput sequencing

Through the high-throughput sequencing library construction method, combined with multiple PCR and internal reference sequence amplification, the problem of cumbersome detection of FH gene mutations in the prior art and the MED12 gene mutations has been solved, and the uterine leiomyoma has been achieved. Accurate detection of FH and MED12 gene mutations simplifies operation and reduces costs, making them suitable for clinical screening.

CN118127154BActive Publication Date: 2024-11-22XIAMEN SPACEGEN BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311835395.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-28
Publication Date
2024-11-22
Estimated Expiration
2043-12-28

AI Technical Summary

Technical Problem

The prior art is complicated to detect FH gene mutations in uterine leiomyomas, and is costly, and fails to detect MED12 gene mutations at the same time, resulting in insufficient comprehensive screening for hereditary leiomyoma disease and renal cell carcinoma.

Method used

Using a library construction method based on high-throughput sequencing, multiple PCR amplification and introduction of internal reference sequence amplification, single-tube PCR library detection FH and MED12 gene mutations were achieved, and combined with optimized PCR reaction procedures and RingCap-Taq enzymes, simplifying Operate and reduce sample input.

Benefits of technology

It realizes accurate and rapid detection of FH and MED12 gene mutations in uterine leiomyoma, simplifies experimental operations, reduces costs, and assists in screening of hereditary leiomyoma disease and renal cell carcinoma, which is suitable for clinical testing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118127154B_ABST
    Figure CN118127154B_ABST
Patent Text Reader

Abstract

The present invention discloses a library construction method for detecting FH and MED12 gene mutations in uterine leiomyoma based on high-throughput sequencing, and belongs to the field of biotechnology. The present invention is based on multiplex PCR amplicon targeted sequencing, first using a specific modified amplification primer SEQ ID NO.1-82 (GSP) for the target region to perform accurate PCR amplification enrichment on the target sequence of the DNA template, and then using a pair of adapter amplification primers SEQ ID NO.83-84 with a sequencing adapter sequence, the enriched product is amplified and a sequencing adapter is added, and the construction of the sequencing library is completed by two-step PCR. The library construction method provided by the present invention can be used for qualitative detection of FH gene and MED12 mutations in uterine leiomyoma tissue samples / peripheral blood samples, and auxiliary hereditary leiomyoma and renal cell carcinoma (HLRCC) syndrome screening.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and in particular relates to a library construction method for detecting FH and MED12 gene mutations in uterine leiomyoma based on high-throughput sequencing. Background Art

[0002] Uterine leiomyoma is the most common benign tumor in the female reproductive system. The main gene mutations include MED12 mutation, HMGA2, HMGA1 rearrangement, COL4A5, COL4A6 deletion, and FH mutation. Among them, the FH gene encodes fumarate hydratase, located on chromosome 1q42.3-q43, with a size of about 22kb and 10 exons. The gene product is FH, which is a key enzyme in the tricarboxylic acid cycle that catalyzes the reaction of fumarate + H2O-malate. Germline mutations in the FH gene cause hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC), which is an autosomal dominant syndrome characterized by uterine, skin leiomyoma and renal cell carcinoma (RCC). FH gene mutation causes biallelic inactivation, resulting in complete loss or reduction of FH activity, causing accumulation of intracellular fumaric acid, enhanced glycolysis, and stable expression of hypoxia-inducible factor 1α (HIF-1α) that is independent of the hypoxic environment, changing the intracellular microenvironment, and thus facilitating tumorigenesis.

[0003] The types of gene mutations in FH-deficient leiomyoma include systemic mutations and germline mutations. Studies have shown that systemic mutations of the FH gene are more common than germline mutations, and systemic mutations of the FH gene are not related to HLRCC. FH immunohistochemistry cannot replace genetic testing, and using only FH immunohistochemistry to screen HLRCC patients will result in missed diagnosis. Genetic testing is the gold standard for diagnosing FH-deficient uterine leiomyoma.

[0004] According to literature reports, in the molecular mechanism of uterine leiomyoma formation, the vast majority of FH-deficient patients are due to FH gene heterozygosity loss (LOH) leading to biallelic FH inactivation, somatic MED12 mutations and gene copy number loss. For sporadic uterine leiomyoma, the most common cause is MED12 gene mutation. Including the detection of MED12 gene can help assist in the screening of hereditary leiomyoma and renal cell carcinoma (HLRCC) syndrome.

[0005] At present, the clinical method for FH gene detection is mainly first-generation sequencing. Since there is no clear hotspot mutation in the FH gene, first-generation sequencing detection needs to cover the 10 exons of the FH gene and requires 10 pairs of amplification primers to perform 10 PCR reactions and 10 sequencing reactions. The experimental operation is cumbersome and costly, and the detection of the MED12 gene is not included. Summary of the invention

[0006] In view of the important clinical significance of FH and the molecular mechanism of uterine leiomyoma, the present invention provides a library construction method for detecting FH and MED12 gene mutations in uterine leiomyoma based on high-throughput sequencing, which can realize single-tube PCR library construction to complete FH and MED12 gene mutation detection. At the same time, internal reference sequence amplification (Ref_gene-1 to Ref_gene-14) is introduced to realize the detection of FH gene copy number, which has the advantages of simple operation and small sample input. The library construction method provided by the present invention can be used for qualitative detection of FH gene and MED12 mutations in uterine fibroid tissue samples / peripheral blood samples, and assist in the screening of hereditary leiomyoma and renal cell carcinoma (HLRCC) syndrome.

[0007] The principle of the library construction method of the present invention is based on multiplex PCR amplicon targeted sequencing. First, the target sequence of the DNA template is accurately amplified and enriched using a specific modified amplification primer (GSP) for the target region, and then a pair of adapter amplification primers with sequencing adapter sequences are used to amplify the enriched product and add sequencing adapters, and the construction of the sequencing library is completed by two-step PCR.

[0008] The present invention combines the use of an optimized PCR reaction program and a highly specific RingCap-Taq enzyme to realize library construction for high-throughput sequencing of target sequences in sample nucleic acids on a common PCR platform, thereby achieving accurate and rapid detection of multi-gene multi-target mutations.

[0009] The primer sequences used in the design and application of the present invention are shown in Table 1 below:

[0010] Table 1

[0011]

[0012]

[0013]

[0014] Among them, "NNNNNNN" in the Ill-iXX-P5 and Ill-iXX-P7 sequences is the index, which can be replaced according to the index sequence used, and the primer name can be modified to the corresponding number, such as ll-i01-P5 and Ill-i01-P7.

[0015] In order to realize single-tube PCR library construction to detect FH and MED12 gene mutations, a library construction method for detecting FH and MED12 gene mutations in uterine leiomyoma based on high-throughput sequencing is provided:

[0016] 1. Use the optimized PCR enrichment reaction solution (refer to Tables 2 and 3), and use the DNA sample as a template to amplify the target gene sequence according to the procedure in Table 4 to obtain the PCR product.

[0017] Table 2. Basic formula of PCR enrichment reaction solution

[0018]

[0019]

[0020] Table 3. Primer MIX formula

[0021]

[0022]

[0023] Table 4. Enrichment reaction amplification procedure

[0024]

[0025] 2. Purify the PCR product with magnetic beads to obtain the enriched product.

[0026] 3. Use the sequencing adapter ligation reaction solution prepared with the adapter amplification primer with the sequencing adapter sequence and the tag sequence (Index) (the formula is shown in Table 5) for the enriched product, and perform the second-round amplification according to the procedure in Table 6.

[0027] Table 5. Formula of sequencing adapter ligation reaction solution

[0028]

[0029] Table 6. Adapter ligation reaction amplification procedure

[0030]

[0031] 4. After the amplified product is purified with magnetic beads, the library of the sample is obtained.

[0032] 5. Use the library for the next step of detection by a high-throughput sequencing instrument to obtain the target sequence information, that is, the fastq file.

[0033] 6. The fastq file is analyzed and processed by bioinformatics for data quality control, sequence alignment, mutation annotation, and copy number analysis. Among them, the principle of copy number analysis is to calculate the ratio CNV-Ratio of the coverage depth ratio of each exon of the FH gene to the baseline ratio of the corresponding exon. If CNV-Ratio ≤ 0.8, it is determined that copy number deletion has occurred in this exon; if CNV-Ratio ≥ 1.2, it is determined that copy number deletion has not occurred in this exon; if 0.8 < CNV-Ratio < 1.2, it is indicated that copy number deletion may exist in this exon.

[0034] The above-mentioned library construction method for detecting FH and MED12 gene mutations in uterine leiomyoma based on high-throughput sequencing includes primer design and optimization of experimental procedures. The library only takes the illumina platform connector as an example, and also replaces different sequencing connector sequences according to the primer design ideas to achieve compatibility with different sequencing platforms, including MGI, ion torrent, etc.

[0035] Compared with the prior art, the present invention has the following beneficial effects:

[0036] 1) The detection of FH mutation and MED12 mutation is integrated. Since the two genes are mutually exclusive in the formation mechanism of uterine leiomyoma, the detection result of MED12 mutation can further assist the screening of hereditary leiomyoma and renal cell carcinoma (HLRCC) syndrome; 2) Through primer design, single-tube PCR library construction is realized to complete the detection of FH and MED12 gene mutations. Compared with the first-generation sequencing detection that requires 10 tubes of PCR amplification and 10 sequencing reactions, it has the advantages of simple operation and small sample input; 3) By introducing internal reference sequence amplification and baseline sample analysis, the detection of FH gene copy number is realized; 4) The amplification length of all primer pairs is controlled within 200bp, which is suitable for DNA library construction from blood samples or paraffin samples that have been degraded to a certain extent. The present invention solves the shortcomings of the current first-generation sequencing detection of FH mutations and is more suitable for clinical detection. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 This is a flowchart of the sequencing data analysis in Example 1.

[0038] Figure 2 This is a graph showing the quality control results of the 6 sample library fragments in Example 1.

[0039] Figure 3 This is a schematic diagram of the normal FH gene copy number in Example 2. The bar graph represents an amplicon, and the ratio of the amplicon coverage ratio of all FH mutations to the baseline is ≥1.2, indicating that the FH gene copy number of the sample is normal.

[0040] Figure 4 Schematic diagram of FH gene copy number loss in Example 2. The bar graph represents an amplicon, and the ratio of the amplicon coverage ratio of all FH mutations to the baseline is ≤0.8, indicating that the FH gene in this sample has a whole gene copy number loss. DETAILED DESCRIPTION

[0041] Example 1

[0042] The quality control of sequencing libraries is the guarantee of the accuracy of sequencing test results, which is divided into pre-sequencing library quality control and post-sequencing data quality control. The quality control before sequencing includes library concentration and library fragment quality control; the quality control of library data after sequencing includes indicators such as Q30, sequencing depth, uniformity, and on-target rate. In order to verify that the library construction method has good library construction quality control data, 6 extracted uterine leiomyoma DNA samples were tested, and the library concentration, library fragments and sequencing quality control data results were statistically analyzed, which specifically includes the following steps:

[0043] 1. Use the optimized PCR enrichment reaction solution (see Table 2 and Table 3) and amplify the target gene sequence according to the procedure in Table 4 using the DNA sample as a template to obtain a PCR product.

[0044] 2. Purify the PCR product with magnetic beads to obtain the enriched product.

[0045] 3. Use the adapter amplification primers with sequencing adapter sequence and index sequence (Index) to prepare the sequencing adapter ligation reaction solution (the formula is shown in Table 5) to perform a second round of amplification on the enriched product according to the procedure in Table 6.

[0046] 4. After the amplified product is purified using magnetic beads, the sample library is obtained.

[0047] 5. The library is used for the next step of high-throughput sequencing instrument detection to obtain the target sequence information, i.e., fastq file.

[0048] 6. Fastq files were processed by bioinformatics analysis for data quality control, sequence alignment, mutation annotation and copy number analysis. For details, see Figure 1 .

[0049] The quality control of the library fragments constructed by the technology of the present invention for 6 cases of uterine leiomyoma is as follows Figure 2 The statistics of sequencing library and sequencing data quality control are shown in Table 7. Figure 2 The capillary electrophoresis fragment quality control of the library shows that the main peak of the library of the 6 samples is between 280-320bp, which is consistent with the expected library fragment size. In addition, there is no small fragment peak caused by primer dimers in the library, indicating the rationality of the primer design. From the statistics of sequencing library and sequencing data quality control in Table 7, it can be seen that the library concentration is greater than 10ng / μL, which can meet the requirements of library loading. In the quality control of sequencing data, indicators such as uniformity, Q30 and on-target rate all performed well.

[0050] Table 7. Statistics of sequencing libraries and sequencing data quality control for 6 samples

[0051]

[0052] The quality control results of the 6 sample libraries and sequencing data showed that the library construction technology of the present invention has good performance in library quality control and sequencing data quality control, and can provide quality control guarantee for the detection of FH and MED12 gene mutations.

[0053] Example 2

[0054] In order to verify the accuracy of the library construction technology of the present invention for detecting FH and MED12 gene mutations, 24 clinical FFPE samples of uterine leiomyoma with FH gene mutations detected by first-generation sequencing were selected to construct libraries for detecting FH and MED12 gene mutations. The experimental operation was referred to Example 1.

[0055] The test results of 24 clinical samples are shown in Table 8 below. The positive coincidence rate of the FH gene mutation detected by this technology and the first-generation sequencing was 100% (13 / 13); among the samples that were negative for FH gene mutation by first-generation sequencing, three samples (FH-S8, FH-S12, and FH-S19) were detected as FH gene full gene copy number deletion, which was consistent with the sample immunohistochemistry FH defect type, while the copy number test results of the samples with positive FH gene mutation and normal FH histochemistry were all normal. For a better interpretation of the CNV test results, please refer to the attached Figure 3 and 4 Schematic diagram of the positive and negative results of copy number detection.

[0056] In addition, a G44V mutation in the MED12 gene was detected in a sample (FH-S15) that was FH-deficient by immunohistochemistry, and the results of immunohistochemistry need to be further reviewed.

[0057] This example verifies the accuracy of the entire technology by comparing it with the first-generation sequencing test results. Not only is the positive coincidence rate 100%, but compared with the first-generation sequencing, it can also detect the copy number variation of the FH gene and the MED12 gene mutation that is not covered by the first-generation sequencing.

[0058] Table 8. Positive site detection results

[0059]

[0060] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A multiplex PCR primer for constructing a uterine leiomyoma FH and MED12 gene mutation library based on high-throughput sequencing, characterized in that: The PCR primer sequences are shown in SEQ ID NO.1-82.

2. A method for constructing a library for detecting FH and MED12 gene mutations in uterine leiomyoma based on high-throughput sequencing, characterized in that: The library construction method comprises the following steps: (1) Take the sample to be tested; (2) using the multiplex PCR primers described in claim 1 to perform a multiplex PCR reaction to amplify the sample to be tested and obtain a multiplex PCR product; (3) After constructing a library of the obtained multiplex PCR products, high-throughput sequencing is performed to obtain the detection results.

3. The library construction method according to claim 2, characterized in that The system of the multiplex PCR reaction in step (2) is: RingCap buffer 10×2.5μL, MgCl225mM 4μL, dNTPs 10μM 1μL, primer MIX 2μL, H2O10.25μL, RingCap-Taq enzyme 5U / ul 0.25μL, DNA 5ng / ul 5μL, with a total volume of 25μL; the primer MIX is a mixture of the multiplex PCR primers described in claim 1; the specific composition of the primer MIX is shown in the following table:

4. The library construction method according to claim 3, characterized in that The procedure of the multiplex PCR reaction is shown in the following table:

5. The library construction method according to any one of claims 2 to 4, characterized in that: The sample to be tested is FFPE sample, fresh tissue or peripheral blood genomic DNA.

6. A library constructed by the library construction method according to any one of claims 1 to 4.

7. The library constructed by the library construction method according to claim 5.

8. Use of the multiplex PCR primers according to claim 1 in constructing a FH and MED12 gene mutation library of uterine leiomyoma.